Eli Lilly's legal strategy against compounding pharmacies reflects a new phase in the GLP-1 market, as they seek to eliminate non-name-brand competition amid product shortages.
The FDA's shortage list allowed compounding pharmacies to produce their own versions of GLP-1 drugs, leading to a market influx that Eli Lilly is now targeting aggressively.
Despite the legal pushback, the compounding of tirzepatide and similar GLP-1 medications has grown, with millions estimated to be using these alternative treatments widely available online.
Eli Lilly’s ongoing lawsuits against misleading claims about compounded tirzepatide highlight the complexities of ensuring compliance and consumer protection in a rapidly evolving pharmaceutical landscape.
Collection
[
|
...
]